BG
ALXN

BlackRock Group’s Alexion Pharmaceuticals ALXN Stock Holding History

BlackRock Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$243M Sell
1,987,406
-44,066
-2% -$5.39M 0.12% 216
2016
Q3 		$249M Sell
2,031,472
-3,823
-0.2% -$492K 0.13% 194
2016
Q2 		$238M Sell
2,035,295
-13,527
-0.7% -$1.92M 0.12% 193
2016
Q1 		$285M Sell
2,048,822
-381,110
-16% -$56M 0.15% 153
2015
Q4 		$464M Sell
2,429,932
-17,479
-0.7% -$3.05M 0.26% 80
2015
Q3 		$383M Buy
2,447,411
+105,757
+5% +$19.3M 0.22% 102
2015
Q2 		$423M Buy
2,341,654
+235,956
+11% +$40.7M 0.23% 98
2015
Q1 		$365M Sell
2,105,698
-24,768
-1% -$4.48M 0.2% 112
2014
Q4 		$394M Buy
2,130,466
+147,089
+7% +$27.3M 0.21% 106
2014
Q3 		$329M Buy
1,983,377
+23,059
+1% +$3.79M 0.19% 113
2014
Q2 		$306M Buy
1,960,318
+115,407
+6% +$18.2M 0.18% 130
2014
Q1 		$281M Buy
1,844,911
+358,961
+24% +$57.1M 0.18% 133
2013
Q4 		$197M Buy
1,485,950
+59,271
+4% +$7.11M 0.13% 178
2013
Q3 		$166M Sell
1,426,679
-5,074
-0.4% -$557K 0.11% 205
2013
Q2 		$132M Buy
+1,431,753
New +$138M 0.1% 235

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BlackRock Group's ALXN Position: Q4 2016 in Review

BlackRock Group reduced its Alexion Pharmaceuticals (ALXN) stake by 2.2% in Q4 2016, selling an estimated $5.39M and leaving 1,987,406 shares worth $243M. The position accounts for 0.12% of the portfolio, ranked #216.

BlackRock Group first reported a position in ALXN in Q2 2013 and has held it in 15 quarters since. The position peaked at $464M in Q4 2015. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

  • BlackRock Group held 1,987,406 shares of Alexion Pharmaceuticals worth $243M as of Q4 2016.
  • BlackRock Group sold 44,066 Alexion Pharmaceuticals shares in Q4 2016, an estimated $5.39M.
  • Alexion Pharmaceuticals made up 0.12% of BlackRock Group's portfolio in Q4 2016, its #216 holding.
  • BlackRock Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Alexion Pharmaceuticals position peaked at $464M in Q4 2015.
  • 548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.